Literature DB >> 28876282

Outcomes of Preexposure Prophylaxis Referrals From Public STI Clinics and Implications for the Preexposure Prophylaxis Continuum.

Ramona Bhatia, Laxmi Modali, Matthew Lowther, Nancy Glick, Margo Bell, Sarah Rowan, Kristin Keglovitz, John Schneider.   

Abstract

BACKGROUND: Human immunodeficiency virus preexposure prophylaxis (PrEP) uptake remains low in high-risk populations. Sexually transmitted infection (STI) clinics reach PrEP-eligible persons and may be ideal settings to model PrEP implementation.
METHODS: Consenting PrEP-eligible patients identified at Chicago Department of Public Health STI Clinics were actively referred to PrEP partner sites between June 1, 2015, and May 31, 2016. Outcomes included successful contact by a partner site, linkage to a partner site, and receipt of a PrEP prescription. Bivariable and time to event analyses were conducted to determine significant associations of outcomes.
RESULTS: One hundred thirty-seven patients were referred; 126 (92%) were men who have sex with men, and mean age was 29 years. Ninety-eight (72%) were contacted by a PrEP partner, 43 (31%) were linked, and 40 (29%) received a prescription. Individuals aged 25 years and older were more likely to link (odds ratio, 3.10; 95% confidence interval, 1.30-7.41) and receive a PrEP prescription (odds ratio, 2.70; 95% confidence interval, 1.12-6.45) compared with individuals 24 years and younger. The average time between each step was greater for those 24 years and younger compared with those aged 25 years and older for all steps. Time to event analyses revealed that those aged 25 years and older were significantly more likely to receive a prescription compared to those aged 24 years and younger (hazard ratio, 3.62; 95% risk limits, 1.47-8.92).
CONCLUSIONS: Preexposure prophylaxis active referrals from STI clinics to partner sites are feasible, though drop out was prominent in the initial steps of the continuum. Youth were less likely to link or receive prescriptions, indicating the need for tailored interventions for this vulnerable population.

Entities:  

Mesh:

Year:  2018        PMID: 28876282     DOI: 10.1097/OLQ.0000000000000690

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  16 in total

1.  HIV Pre-Exposure Prophylaxis Implementation Cascade Among Health Care Professionals in the United States: Implications from a Systematic Review and Meta-Analysis.

Authors:  Chen Zhang; James McMahon; Kevin Fiscella; Sarahmona Przybyla; Amy Braksmajer; Natalie LeBlanc; Yu Liu
Journal:  AIDS Patient Care STDS       Date:  2019-12       Impact factor: 5.078

2.  Which Patients in the Emergency Department Should Receive Preexposure Prophylaxis? Implementation of a Predictive Analytics Approach.

Authors:  Jessica P Ridgway; Ellen A Almirol; Alvie Bender; Andrew Richardson; Jessica Schmitt; Eleanor Friedman; Nicola Lancki; Ivan Leroux; Nina Pieroni; Jessica Dehlin; John A Schneider
Journal:  AIDS Patient Care STDS       Date:  2018-04-19       Impact factor: 5.078

Review 3.  Get2PrEP: An Electronic Medical Record Laboratory Comment Increased Safe Sex Counseling But Not Preexposure Prophylaxis Services at a Large Urban Academic Medical Center in Northern Manhattan.

Authors:  Rebecca Spicehandler; Jason Zucker; Caitlin Yumori; Matthew Adan; Caroline Carnevale; Deborah Theodore; Delivette Castor; Kathrine Meyers; Susan Whittier; Michael T Yin; Alwyn Cohall; Susan Olender; Peter Gordon; Magdalena E Sobieszczyk
Journal:  Sex Transm Dis       Date:  2022-07-29       Impact factor: 3.868

4.  Evaluation of an HIV Pre-Exposure Prophylaxis Referral System: From Sexual Health Center to Federally Qualified Health Center Pre-Exposure Prophylaxis Clinic.

Authors:  Rebecca Lillis; Jeremy Beckford; Joshua Fegley; Julia Siren; Bruce Hinton; Samuel Gomez; Stephanie N Taylor; Isolde Butler; Jason Halperin; Meredith Edwards Clement
Journal:  AIDS Patient Care STDS       Date:  2021-08-26       Impact factor: 5.944

5.  Implementing PrEP Services in Diverse Health Care Settings.

Authors:  Elissa Z Faro; Joanne E Mantell; Tatiana Gonzalez-Argoti; Susie Hoffman; Zoe Edelstein; Benjamin Tsoi; Laurie J Bauman
Journal:  J Acquir Immune Defic Syndr       Date:  2022-07-01       Impact factor: 3.771

6.  A modeling framework to inform preexposure prophylaxis initiation and retention scale-up in the context of 'Getting to Zero' initiatives.

Authors:  Aditya S Khanna; John A Schneider; Nicholson Collier; Jonathan Ozik; Rodal Issema; Angela di Paola; Abigail Skwara; Arthi Ramachandran; Jeannette Webb; Russell Brewer; William Cunningham; Charles Hilliard; Santhoshini Ramani; Kayo Fujimoto; Nina Harawa
Journal:  AIDS       Date:  2019-10-01       Impact factor: 4.177

7.  Patient Disengagement From an HIV Preexposure Prophylaxis Program in a Sexually Transmitted Disease Clinic.

Authors:  Julia C Dombrowski; Matthew R Golden; Lindley A Barbee; Christine M Khosropour
Journal:  Sex Transm Dis       Date:  2018-09       Impact factor: 2.830

8.  Reaching Those Most at Risk for HIV Acquisition: Evaluating Racial/Ethnic Disparities in the Preexposure Prophylaxis Care Continuum in Baltimore City, Maryland.

Authors:  Christina M Schumacher; Xueting Tao; Aruna Chandran; Errol Fields; Ashley Price; Adena Greenbaum; Jacky M Jennings
Journal:  J Acquir Immune Defic Syndr       Date:  2021-08-15       Impact factor: 3.771

9.  Successful Linkage to Pre-Exposure Prophylaxis for HIV Prevention Using a Multicomponent Implementation Strategy Among the Uninsured/Underinsured.

Authors:  Rupa R Patel; Amy S Nunn; Kenneth H Mayer; Timothy McBride; Ross C Brownson; Cheryl Oliver; Maria M Perez; Laura C Harrison; Amber Salter; John S Crane; Philip A Chan
Journal:  AIDS Patient Care STDS       Date:  2019-01-16       Impact factor: 5.944

10.  Predictors of HIV Preexposure Prophylaxis Initiation Among Public Health Clients in Rural and Small Urban Areas in Iowa.

Authors:  M Bryant Howren; Shelby L Francis; Linnea A Polgreen; Cody Shafer; Angela Hoth; Michael E Ohl
Journal:  Public Health Rep       Date:  2020-10-27       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.